Matthew Galsky, M.D., FASCO, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, will present the late-breaking abstract in a rapid oral presentation titled “Updated clinical results ...

Defining publication bias and discussing its negative influence on scientific literature, including introduction of bias in favor of positive results. Determining the number of oral abstracts ...

All students in the oral presentation must submit at least one slide to accompany their presentation. All presentation slides must be submitted in PowerPoint (PPT) format. Slides should not include ...

Abstract: English is employed in many tertiary education institutions where oral presentation assignments are delivered entirely in English. To support students who learn English as an Additional ...

We have combined laser capture microdissection (LCM) sample collection of oral epithelial tissue with microarray analysis to study gene expression in oral cancer. Matched normal and malignant oral ...

An FDA risk review has cleared the way for canine freeze-dried plasma, a shelf-stable product that could expand transfusion options in emergencies. A freeze-dried plasma product for canine patients is ...

The 2026 Vet Tech Purrposium is a virtual CE event to be held on March 26. Sponsored by Zoetis, this CE event was created for veterinary technicians and features veterinary technician speakers with ...

Objective We aim to compare the effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on the gut microbiota through longitudinal analysis. Design Healthy volunteers ...

Bionano Symposium 2026 continues with Day 3: OGM Making its Mark in Constitutional Genetic Disorders on February 25, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...

The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, ...

Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer ...